RPM International stock falls premarket as soft guidance offsets earnings beat
RpM International Inc.'s stock (RPM) slid 5% in premarket trade Thursday after the paint and building materials company's below-consensus guidance offset a fiscal third-quarter earnings beat. Medina, Ohio-based RPM posted net income of $26.9 million, or 21 cents a share, for the quarter to Feb. 28, down from $33.0 million, or 25 cents a share, in the year-earlier period. Adjusted per-share earnings came to 37 cents, ahead of the 31 cent FactSet consensus. Sales rose 5.7% to $1.516 billion from $1.434 billion a year ago, also ahead of the $1.470 billion FactSet consensus. Sales were boosted by higher spending on infrastructure and reshoring projects, CEO Frank C. Sullivan said in a statement. by geography, sales were strongest in the U.S. and Latin America, up 8% and 7.3% respectively. They were weakest in Europe where they fell 3.6%. The company is now expecting fiscal fourth-quarter sales to be flat from a year ago and for adjusted EBIT to be flat to lower in a high single-digit range. The FactSet consensus is for EPS to be 3 cents higher than in the year-earlier quarter and for sales to rise 2%. The stock has gained 3% in the last 12 months, while the S&P 500 has fallen 9%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-06-23 0719ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth